Effect of spironolactone on C-reactive protein levels in patients with heart disease

Valerie Godfrey, Colin A.J. Farquharson, John E. Macdonald, Kok-Meng Yee, Allan D. Struthers

    Research output: Contribution to journalArticlepeer-review

    22 Citations (Scopus)


    Animal evidence shows that aldosterone is pro-inflammatory and that aldosterone blockade is anti-inflammatory. Therefore part of the beneficial effect of aldosterone blockade that might contribute to it reducing mortality could be an anti-inflammatory effect. However, there are no previous data on whether aldosterone blockade is anti-inflammatory in man. We performed 4 separate studies to investigate whether spironolactone treatment would reduce levels of C-reactive protein (CRP), a marker of inflammation, in serum samples taken from patients suffering from different degrees of heart failure. We found in all 4 studies that spironolactone had no significant effect compared with placebo, on CRP levels in these patients. These studies provide evidence against the hypothesis that the clinical benefits produced by aldosterone blockade are due to it having anti-inflammatory effects.
    Original languageEnglish
    Pages (from-to)282-284
    Number of pages3
    JournalInternational Journal of Cardiology
    Issue number2
    Publication statusPublished - 25 Apr 2007


    Dive into the research topics of 'Effect of spironolactone on C-reactive protein levels in patients with heart disease'. Together they form a unique fingerprint.

    Cite this